Cerevel Therapeutics Inc. has identified compounds acting as muscarinic M4 receptor agonists reported be useful for the treatment of pain, sleep disorders, schizophrenia, substance abuse and dependence, drug-induced dyskinesia, and Alzheimer's and Parkinson's disease.